Analysts forecast that NovaBay Pharmaceuticals, Inc. (NYSE:NBY) will report sales of $5.01 million for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for NovaBay Pharmaceuticals’ earnings. The highest sales estimate is $5.10 million and the lowest is $4.92 million. NovaBay Pharmaceuticals reported sales of $3.44 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 45.6%. The business is scheduled to report its next earnings report on Thursday, November 9th.

On average, analysts expect that NovaBay Pharmaceuticals will report full-year sales of $5.01 million for the current year, with estimates ranging from $18.66 million to $19.00 million. For the next financial year, analysts anticipate that the firm will report sales of $26.57 million per share, with estimates ranging from $25.13 million to $28.00 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that that provide coverage for NovaBay Pharmaceuticals.

NovaBay Pharmaceuticals (NYSE:NBY) last released its quarterly earnings results on Thursday, August 10th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01. The business had revenue of $4.12 million during the quarter, compared to analyst estimates of $4.57 million. NovaBay Pharmaceuticals had a negative return on equity of 280.84% and a negative net margin of 108.38%.

Several equities research analysts have recently weighed in on NBY shares. Maxim Group reiterated a “hold” rating on shares of NovaBay Pharmaceuticals in a report on Saturday, May 13th. Zacks Investment Research upgraded NovaBay Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 17th. Roth Capital started coverage on NovaBay Pharmaceuticals in a report on Monday, June 5th. They issued a “buy” rating and a $5.50 price target on the stock. Finally, HC Wainwright set a $6.00 price target on NovaBay Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, August 11th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. NovaBay Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $7.00.

WARNING: This story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at

NovaBay Pharmaceuticals (NYSE NBY) traded up 1.15% during midday trading on Friday, reaching $4.40. The company had a trading volume of 7,216 shares. The company has a 50-day moving average of $4.41 and a 200-day moving average of $3.70. NovaBay Pharmaceuticals has a 12-month low of $2.25 and a 12-month high of $5.09. The stock’s market capitalization is $67.36 million.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, formerly NovaCal Pharmaceuticals, Inc, is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox.

Get a free copy of the Zacks research report on NovaBay Pharmaceuticals (NBY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for NovaBay Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.